Related Experiment Video

Updated: May 25, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Causes of thrombocytopenia in chronic hepatitis C viral infection

Makoto Osada1, Makoto Kaneko, Minoru Sakamoto

  • 1Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Japan.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|February 14, 2012
PubMed

Insights

Platelet counts decrease in advanced liver disease stages. Splenomegaly and von Willebrand factor (vWF) are key factors in thrombocytopenia, alongside vascular endothelial dysfunction in chronic hepatitis C virus (HCV) infection.

Area of Science:

  • Hepatology
  • Hematology
  • Virology

Background:

  • Chronic hepatitis C virus (HCV) infection is a significant global health concern.
  • Thrombocytopenia, a low platelet count, is a common complication in advanced liver disease.
  • Understanding the mechanisms behind thrombocytopenia in HCV is crucial for patient management.

Purpose of the Study:

  • To investigate factors associated with thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection.
  • To explore the relationship between liver disease severity and platelet count.
  • To identify specific clinical and biochemical markers linked to reduced platelet levels.

Main Methods:

  • Retrospective study of 89 patients with chronic hepatitis C virus (HCV) infection.
  • Categorization of patients into chronic hepatitis (CH), liver cirrhosis (LC), and LC with hepatocellular carcinoma (LC + HCC) groups.
  • Multiple regression analysis to identify explanatory variables for thrombocytopenia.

Main Results:

  • Platelet count showed a significant decrease with advancing stages of liver disease.
  • Splenomegaly and elevated von Willebrand factor (vWF) were identified as significant factors correlating with thrombocytopenia.
  • Soluble thrombomodulin, a marker of endothelial dysfunction, increased with liver fibrosis and correlated with vWF and inversely with platelet count.

Conclusions:

  • Splenomegaly is a major contributor to thrombocytopenia in chronic HCV, but other factors are also involved.
  • Vascular endothelial dysfunction, indicated by increased soluble thrombomodulin and vWF, plays a role in HCV-associated thrombocytopenia.
  • These findings highlight the complex multifactorial nature of thrombocytopenia in chronic HCV infection.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.